14.09.2015 13:22:23
|
Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 14 September 2015 - On 30 April 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17.5 billion to be executed during a 12-month period beginning 30 January 2015.
Further information
Media: | ||
Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Kasper Veje | +45 3079 8519 | kpvj@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Company Announcement No 55 / 2015
This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#1951827
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordiskmehr Nachrichten
Analysen zu Novo Nordiskmehr Analysen
29.04.24 | Novo Nordisk Neutral | UBS AG | |
25.04.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
24.04.24 | Novo Nordisk Outperform | Bernstein Research | |
26.03.24 | Novo Nordisk Neutral | UBS AG | |
25.03.24 | Novo Nordisk Overweight | Barclays Capital |